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Although the exact aetiology of inflammatory bowel disease (IBD) is unknown, one hypothesis suggests 
that the inflammation may be the consequence of an altered or pathogenic microbiota in a genetically 
susceptible host. The aim of this study was to assess the frequency of enteral infections in patients with 
relapse of IBD, and to evaluate the clinical utility of faecal calprotectin (FC) and faecal matrixmetallopro-
teinase-9 (MMP-9) in the differential diagnosis of relapses with different origins, and to determine the re-
currence rate of Clostridioides difficile (C. difficile), the hospitalisation and colectomy rate among C. difficile 
positive IBD patients at the end of 4 years follow-up period.
Methods: In this prospective, “real life” study clinical data, serum and stool samples were assessed.
Results: Overall, 135 outpatients with IBD were enrolled [91 IBD patients who relapsed and 44 subjects in cli-
nical remission (control group)]. C. difficile A/B toxins were detected in 42.2% of all cases. Candida was pre-
sented in 9.9% among the enrolled subjects. We found significant difference between FC and MMP-9 values 
in patients in relapse and remission, but not in C. difficile positive and negative cases. Our results revealed an 
association between previous antibiotic use and the rate of toxigenic C. difficile. Toxigenic C. difficile positivity 
recurrence rate was 4.4%. Hospitalisation during follow-up due to IBD was 45.4% and 35% in C. difficile positive 
and negative group, respectively. Value of FC and MMP-9 did not predict the need of hospitalisation.
Conclusions: The occurrences of toxigenic C. difficile and Candida positivity were excessively high in our 
patients in an acute relapse, which suggests the importance of intestinal microbiota in IBD. FC and MMP-9 
has no diagnostic value to differentiate between infection-induced and natural relapse. In our study was 
confirmed that hospitalisation rate was higher in C. difficile positive cases, but we did not find any rela-
tionship on long-term period.
KEYWORDS: Clostridioides difficile, ulcerative colitis, Crohn’s disease, faecal calprotectin, matrix metallopro-
teinase-9
Introduction
The course of the inflammatory bowel diseases (IBD: 
Crohn’s disease – CD – and ulcerative colitis – UC) are ch-
ronic or intermittent and coloured by multiple flare-ups, 
despite long-term maintenance treatment in about half of 
the patients (1, 2). Just as with the initial manifestation of 
IBD, the factors which cause subsequent relapses are also 
ambiguous in most cases; however, an infective agent may 
play a role in both the manifestation and the relapse (3).
Some animal experiments suggest a role is played by 
bacteria in the pathogenesis of IBD: interleukin-10 knoc-
kout, germ-free mice do not develop colitis; however, in-
terleukin-2-deficient mice develop spontaneous colitis 
after Escherichia coli exposure, but not with Bacteroides 
vulgatus exposure (4). Although the aetiology of IBD has 
not been unequivocally clarified, an altered intestinal 
immune response due to the interaction of several envi-
ronmental and genetic factors is observable, which may 
lead to inadequate gut flora compound and function, thus 
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making the intestine vulnerable to superinfections like the 
infections caused by toxigenic Clostridioides difficile (C. dif-
ficile) (5, 6, 7). C. difficile infections came to the front since 
epidemiological data showed high prevalence of toxin-
producing isolates (8, 9) among IBD patients. Current data 
suggest that in patients with CD or UC, infections caused 
by this anaerobic bacterium occur more frequently than in 
the general population (10). The significance of toxigenic 
C. difficile positivity manifests not only in its increasing in-
cidence, growing antibiotic resistance and severe disease 
course, but also in the magnitude of the infections, which 
also leads to high health care costs. Expansion of C. difficile 
infections is more pronounced in IBD patients; moreover, 
its prevalence has been reported in 5 to 19% in patients 
with active disease (11, 12). According to previous studies, 
the rate of C. difficile infection is approximately 4-5 times 
greater than in non-IBD patients (13, 14). However, most of 
studies are retrospectively performed.
The usual diagnostic tools in case of a relapse of IBD con-
sist of faecal microbiological examination and an evalua-
tion of inflammatory biochemical and stool biomarkers. 
A simply and quickly performing marker would be useful 
as strong point in the differentiation of an infective ori-
gin or exacerbation. Faecal calprotectin (FC) and matrix 
metalloproteinase-9 (MMP-9) are markers that correlate 
with disease activity. FC is a neutrophil leukocyte-deriva-
te protein eligible for distinguishing IBD from functional 
disorders (15). In vitro resistance to degradation allows 
faecal samples to be assayed for reliable calprotectin de-
termination. FC has a high sensitivity in the determination 
of IBD activity; however, elevated levels were also shown 
in intestinal infections, tumours and colon polyps, there-
fore its specificity is less favourable. MMP-9 is a Zn-binding 
neutral proteinase produced by polymorphonuclear cells. 
MMP-9 is one of the major contributors to the breakdown 
and reconstruction of the extracellular matrix (16). Faecal 
MMP-9 and FC in UC patients is an excellent marker of di-
sease activity and shows significant correlation with clini-
cal and endoscopic scores (17).
The objective of this study was to prospectively assess the 
prevalence of enteral infections (especially toxigenic C. dif-
ficile and Candida sp.) among our outpatients with IBD in 
relapse. Patients in remission were examined as a control 
group. In addition, our secondary endpoint was to esti-
mate the utility of clinical and differential diagnoses of FC 
and MMP-9 in cases of both with infection and without in-
fection. The tertiary endpoint was to assess the long-term 
outcome of C. difficile infection in IBD patients. We aimed 
to determine the recurrence rate of C. difficile, the hospita-
lisation and colectomy rate among C. difficile positive IBD 
patients at the end of 4 years follow-up period. 
Patients and methods
Patient selection
91 IBD patients with symptoms of relapse were enrolled 
in our study with 44 control IBD subjects in clinical re-
mission from September, 2012 to July, 2013. All of them 
were outpatients at the 1st Department of Medicine, 
Szeged, Hungary. The medical data of patients were col-
lected prospectively. Clinical data, activity indexes, faecal 
specimens and serum samples were analysed of 91 IBD 
patients who manifested worsening symptoms – indica-
ting a potential relapse – and of 44 IBD patients in remis-
sion. Blood samples were taken from all patients for the 
determination of CRP level (C-reactive protein), platelet 
and leukocyte count, serum iron level and haemoglobin 
level. Faecal samples from every subject were sent to the 
microbiological laboratory of the Institute of Clinical Mic-
robiology, University of Szeged. The clinical activity of CD 
and UC were assessed using the Crohn’s Disease Activity 
Index (CDAI) and with a partial Mayo Score (pMayo), res-
pectively. Relapse was defined as ≥150 points and/or an 
increase of ≥80 points in the CDAI in the case of CD and 
≥2 points in the pMayo score in the case of UC. Immuno-
Table 1. Clinical characteristics of patients at 
the time of enrolment
Relapsing 
group 
(n=91)
Control 
group 
(n=44)
Gender (male/female) 
No. of patients
43/48 26/18
Age 
Years, mean (min-max)
36.8  
(16 to 79)
40  
(19 to 75)
UC/CD
No. of patients
49/42 25/19
Disease location (based on Montreal classification of 
IBD)
L1 15 6
L2 7 6
L3 20 7
E1 11 8
E2 20 6
E3 18 11
Disease duration (years)
Years, mean (min-max)
6.9  
(0 to 26)
10.9  
(0 to 46)
Appendectomy
No. of patients
4 1
Smoking 
No. of patients
17 5
Extraintestinal manifestation
No. of patients
36 9
Immunosuppression
No. of patients
46 25
Gastricacid-suppressant 
agent
No. of patients
25 8
Antibiotic use in previous  
3 months
No. of patients
18 4
Previous C. difficile positivity
No. of patients
23 7
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suppression was defined by Consensus of the European 
Crohn’s and Colitis Organisation (ECCO) (3). Data of the 
patients regarding smoking status, previous appendec-
tomy, perianal involvement, the presence of extraintes-
tinal manifestations of IBD, previous antibiotic use and 
concomitant medications were collected from each sub-
ject. The clinical characteristics of the patients are pre-
sented in Table 1.
Microbiological examination
A microbiological analysis for the presence of enteric 
pathogens (including toxigenic C. difficile, Campylo-
bacter spp., Salmonella spp., Shigella spp., Yersinia spp., 
Candida spp. and in reasonable cases viruses and para-
sites) was carried out at the Institute of Clinical Micro-
biology, Szeged, Hungary. Laboratory diagnosis of to-
xigenic C. difficile was based on ESCMID guideline (18): 
faecal samples were tested for the presence of glutama-
te dehydrogenase (GDH) and toxin A/B using the QUIK 
CHEK COMPLETE (TechLab). Samples with a GDH-posi-
tive, but toxin A/B negative results were further tested 
with toxigenic culture method. Toxigenic culture is one 
of reference method for diagnosing C.difficile infection. 
The basis of this method is isolation of C. difficile and 
testing the toxin production in vitro by a sensitive A/B 
toxin detection method (18).
Measurement of faecal calprotectin and MMP-9
Samples for FC and MMP-9 determination were stored 
at –20 °C until analysed. Faecal specimens were tha-
wed and prepared for a calprotectin assay as descri-
bed by the manufacturer. FC levels were measured by 
a quantitative lateral flow assay (Quantum Blue, Bühl-
mann Labortories, Switzerland). Samples for MMP-9 
determination were thawed and prepared as described 
by the manufacturer. In a few words, one gram of the 
sample was diluted and homogenised in 4 ml of an ice-
cold buffer (0.15M NaCl + 20 mM Tris-HCl, pH: 8.3). The 
suspension was then centrifuged at 1500g for 10 min 
and the supernatant was recentrifuged at 10,000 g for 
10 min. The final supernatant was filtered and stored at 
–20 °C until analysed. MMP9 concentrations were deter-
mined by ELISA method (Quantikine MMP9 assay, R&D 
System, UK).
Statistical analysis
The collected data was analysed statistically, using 
Pearson’s chi-square test, Pearson’s chi-square test with Ya-
tes’ continuity correction and Wilcoxon rank sum test with 
continuity correction. P<0.05 was considered as statisti-
cally significant. For the statistical analysis, SPSS15.0 (SPSS 
Inc., Chicago, IL, USA) was used.
Ethical Considerations
The study was approved by the Regional and Institutional 
Human Medical Biological Research Ethics Committee of 
the University of Szeged (ethical approval number: SZTE-
170/2011).
Results
Infection Rates
Out of the 135 enrolled patients (91 with relapse and 
44 control), 74 subjects were diagnosed with UC and 61 
with CD. Forty-nine UC and 42 CD patients participated 
in the relapse group. The number of UC and CD patients 
was 25 vs. 19 subjects in the control group (Table 1.). 
In the relapsing group the mean value of the Crohn’s 
Disease Activity Index (CDAI) was 219.6 points (in the 
range of: 105 to 450) and the mean value of the pMayo 
score in the case of UC was 5.2 (in the range of: 3 to 
9) points at the time of enrolment (Table 2.). The most 
frequent disease locations in the relapse cohort were 
left sided and pancolitis (20 and 17 subjects) in the case 
of UC, and pure ileal and the ileocolonic in the case of 
CD (15 and 20 subjects). Approximately half of the pati-
ents were immunosuppressed in the relapse group and 
also in the control group (Table 1. and 2.).
Toxigenic C. difficile or Candida spp. was identified in 53 
of 91 faecal samples taken from relapsing patients; on 
the other hand, 11 of 44 patients had positive microbi-
ological stool findings in the control group in remission 
(p<0.001). 49 participants with positivity of C. difficile 
A/B toxins had been detected among the patients in re-
lapse (53.8%), while toxigenic C. difficile positivity was 
observed in 8 patients (18.2%) in the remission group. 
Other microbiological findings in the relapse group 
were the presence of Candida species (10 patients) in all 
except one subject, who had Salmonella infection. Can-
dida species occurred in 4 patients in the control group. 
In 7 cases we found simultaneous presence of toxigenic 
Table 2. Inflammatory biomarkers and clinical 
activity indices of IBD patients at the time of 
enrolment
Relapsing 
group (n=91)
Control 
group (n=44)
CDAI
mean (min-max)
219.6 (105 to 
450)
60.7  
(0 to 127)
pMayo Score
mean (min-max)
5.2  
(2 to 9)
0.6  
(0 to 2)
FC (μg/g)
median (min-max)
640  
(29 to 14000)
79  
(29 to 860)
Fecal MMP-9 (ng/mL)
mean (min-max)
11.4  
(0 to 168.8)
5.6  
(0 to 23.2)
CRP (mg/L)
mean (min-max)
23.1  
(1 to 202.6)
6.5  
(1 to 40.8)
Leucocytes (G/L)
mean (min-max)
9.8  
(3.8 to 90.6)
7.4  
(3.6 to 15.1)
Thrombocytes (G/L)
mean (min-max)
326  
(88 to 657)
292.7  
(125 to 602)
Serum iron (μmol/L)
mean (min-max)
11.5  
(1.9 to 25.3)
15.1  
(4.3 to 33.1)
Hematocrit (%)
mean (min-max)
39  
(21 to 49)
40  
(33 to 46)
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C. difficile and Candida sp. in relapse group, and in one 
case in the control group (Figure 1.).
A significant difference was revealed between the relapse 
and the control group regarding the positive cases of C. dif-
ficile (P=0.0002). We found that relapse of IBD is a predicting 
factor for C. difficile positivity (P=0.01). 23 subjects in the 
relapse group had previous toxigenic C. difficile positivity 
in their medical history, although only 14 of the currently 
infected patients were positive in the past. Six patients had 
recurrent toxigenic C. difficile positivity in relapsing group 
during follow-up period. Seven of the control subjects had 
positive toxigenic C. difficile results previously, but only 2 of 
currently C. difficile-positive subjects had a medical history 
of C. difficile infections. We did not find a difference between 
CD and UC regarding positive microbiological examination 
findings or toxigenic C. difficile positivity (29 subjects with 
UC and 26 with CD). There was no significant connection 
between disease extension, extraintestinal manifestations, 
perianal involvement, smoking, age, gender, disease durati-
on, immunosuppression and gastricacid-suppressant agent 
use and toxigenic C. difficile positivity. Previous antibiotic 
use was 19.8% in the relapse group and 9% in the control 
group, moreover it was more frequent among C. difficile-
positive subjects (p=0.05). Therefore, previous antibiotic 
use was shown to have a connection to toxigenic C. difficile 
positivity, but other assessed factors did not predict the pre-
sence of C. difficile toxins.
Patients in whom C. difficile toxins had been detected in 
the relapse group were treated with metronidazole. A 
combination of antibiotics was used, or a substitute was 
used for metronidazole (rifaximin or vancomycin) in case 
of metronidazole inefficiency, or if repeated stool exami-
nations continued to be positive. Ciprofloxacin and met-
ronidazol combination was used in case of suspicions 
natural relapse of CD (5 patients). Antibiotic switch was 
needed in 18.8% of C. difficile positive cases in relapsing 
group (50% to vancomycin). Three patients needed hospi-
talisation in a Department of Infectious Diseases due to a 
therapy-resistant case of C. difficile positivity. However, the 
reasonable administration of a supplementary therapy or 
a modification of the maintained treatment was sufficient 
in 45.1% of the cases (oral or topical corticosteroids, 5-ASA 
and anti-TNF-therapy). Twenty two subjects required hos-
pitalisation because of a relapse. Hospitalisation rate was 
not associated with initial level of FC or MMP-9 in natural 
relapse or in C. difficile positive cases.
Long-term outcome
The mean follow-up period was 51 (SD 8.2) months in our 
study. Toxigenic C. difficile positivity recurrence rate was 
4.4%. The hospitalisation rate was 54.8% during follow-up 
period, within that hospitalisation due to IBD was 39.2%, 
due to C. difficile was 2.2% and due to other reasons was 
31.8%. More patients with relapse needed hospitalisation 
during follow-up period (P=0.002) than patients in remis-
sion. Despite that, value of FC and MMP-9 did not predict 
the need of hospitalisation. The rate of hospitalisation due 
to any reason during follow-up period was 54.4% in C. dif-
ficile positive group and 55% in C. difficile negative group 
therefore C. difficile positivity itself did not predict need of 
hospitalisation on long-term period. On the other hand, 
hospitalisation during follow-up due to IBD was 45.4% and 
35% in C. difficile positive and negative group, respectively. 
Colectomy rate during follow-up was 11.8%.
Figure 1. Infection rates among patients with relapse and remission of IBD at the time of 
enrolment
Control group
Salmonella
spp.
1 patient
Toxigenic
C. difficile
49 patients
Candida
spp.
10 patients
7
Candida
spp.
4 patients
Toxigenic
C.difficile
8 patients
1
Relapsing group
P=0.0002
P<0.001
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Laboratory Findings
The mean values of CRP in the relapse and the control 
group were 23.08 mg/L (in the range of: 1 to 202.6 mg/L) 
and 6.46 mg/L (in the range of: 1 to 40.8 mg/L), respec-
tively. CRP was slightly higher in those with CD than in 
those with UC (the mean values of which are: CD: 25.17 
mg/L vs. UC: 21.31 mg/L) in relapse group, but on the ot-
her hand, this difference was similar in the control group 
(the mean values of which are: CD: 9.68 mg/L vs. UC: 4.12 
mg/L). The mean values of the leukocyte and the thrombo-
cytes count, the serum iron and the hematocrit levels were 
9.79 G/L, 326.05 G/L, 11.48 μmol/L and 39% in the relapse 
group, and 7.4 G/L, 292.7 G/L, 15.1 μmol/L and 40% in the 
control group (Table 2.).
Faecal Calprotectin Levels
The median value of FC in those in relapse (640 μg/g, in 
range 29-14000 μg/g) was significantly higher compa-
red to the control group (79 μg/g, in range 29-860 μg/g) 
(P<0.001). FC did not showed difference in relapsing pati-
ents without (with the median value of: 510 μg/g) vs. with 
C. difficile positivity (with the median value of: 690 μg/g).
Faecal MMP-9 Levels
Similarly to FC, faecal MMP-9 levels were higher in the 
relapse group (11.36 ng/mL; in the range of: 0 to 168.79 
ng/ml) compared to the control group (5.61 ng/mL; in the 
range of: 0 to 23.28 ng/mL; P=0.001). We found obvious 
numerical difference between the mean values in cases of 
microbiological (C. difficile or Candida spp.) positive (mean: 
8.0 ng/ml) and negative cases (mean: 14.97 ng/ml) in the 
relapse cohort; however, statistical analysis did not con-
firm the difference. 
Discussion
Enteral infection rate during an IBD relapse, the clinical 
utility of faecal inflammatory markers (FC and MMP-9) and 
long-term outcome after presence of toxigenic C. difficile 
were assessed in this study. The occurrence of toxigenic C. 
difficile positivity was remarkably high in our IBD patients 
(42.2%) compared to data of previous studies. Incidence 
was even higher in cases of relapse, suggesting some con-
nection between flare-ups of IBD and C. difficile positivity. 
A differential diagnosis of a relapse of IBD and C. difficile 
infection is difficult in some cases; furthermore, both can 
occur at the same time, thus a faecal microbiological exa-
mination and tests for both toxins A/B is recommended in 
the event of a relapse, as the evidence-based consensus of 
ECCO also suggests (3).
Some studies suggest that the aetiology of IBD with al-
tered intestinal microbiome is a result of innate genetic 
defects in the intestinal epithelial and mucosal barriers. 
In addition, the aetiological background may involve a 
microbial imbalance in the intestine or dysfunction in the 
intestinal inflammatory cascade, leading to pathologic 
proliferation of cytokines (4). Although an exact aetiology 
of IBD has not been confirmed yet, the importance of mic-
roorganisms in the intestine is obvious. Toxigenic C. difficile 
positivity (53.8%) and Candida (9.9%) colonization were 
the most frequent results of faecal microbiological exami-
nations in our relapse cohort, suggesting an imbalance of 
intestinal microflora.
It is well-known that the infection rate in patients with an 
IBD is greater than in the normal population; infectious 
agents are involved in the etiopathogenesis, but it can also 
initiate a relapse of the IBD (15). IBD is an independent risk 
factor of C. difficile positivity, mainly UC patients are sus-
ceptible to infection, and thus microorganisms have consi-
derable significance in patient management (3, 18–20). In 
our study, the UC/CD ratio in the C. difficile cohort was ap-
proximately equal (25 UC vs. 23 CD subjects).
The disease course of a C. difficile infection can be extre-
mely serious, even life-threatening complications may oc-
cur, which is confirmed beyond a doubt by the mortality 
rate of hospitalised IBD patients with a C. difficile infecti-
on (21). C. difficile infection was not severe in most of the 
cases in our study, serious complications did not occur du-
ring the tenure of the study. However, hospitalisation was 
needed in 13 of 49 cases with positive result of toxigenic 
C. difficile in relapsing group, most of them because of a 
severe flare-up requiring intravenous treatment. It seems 
that toxigenic C. difficile positivity is also a trigger and an 
additive factor in relapse of IBD. Hospitalisation, colectomy 
and mortality rates are higher in a population with toxi-
genic C. difficile positivity (12). In our study was confirmed 
that hospitalisation rate was higher in C. difficile infections, 
but we did not find any relationship on long-term period.
In some studies, antimicrobial and immunomodulator 
agent-exposure has been shown to increase the possi-
bility of a C. difficile infection and carriage (11). Basically, 
any type of antibiotic may be linked with the manifestati-
on of a C. difficile infection; however, the antibiotics most 
commonly connected to an occurrence C. difficile infecti-
on include penicillins, clindamycin, cephalosporins and 
fluoroquinolones (22). Regardless, antibiotic use for IBD 
patients in general seems to be a critical risk factor for the 
development of a C. difficile positivity infection, as our re-
sults showed. The use of immunomodulators specifically 
has not been confirmed in our study to be predictive of 
a C. difficile positivity risk, however. The data available on 
immunomodulators is conflicting; some studies showed an 
increasing risk for C. difficile positivity (11), although others 
did not confirm these results (23). The number of toxigenic 
C. difficile-positive subjects taking immunosuppressants did 
not differ substantially compared to those patients not tre-
ated with immunosuppressants in our study. A correlation 
between C. difficile positivity and the use of gastric acid-
suppressive agents, especially histamine blockers and pro-
ton pump inhibitors, has been suggested (24). However, si-
milarly to our own findings, other observational studies did 
not yield results to support the connection (25).
A strong correlation between intestinal inflammation and 
FC has been confirmed in IBD (26); to note, its value can 
increase in enteral infections also (27). Enhanced levels of 
MMP-9 have been observe in the intestinal tissue in the 
case of IBD and seem to be actively involved in the inflam-
matory and remodelling process (28). In this study, levels 
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of FC and MMP-9 were measured both in cases of infection 
and non-infection. Although we discover higher levels of 
FC and faecal MMP-9 in natural relapses than in infection-
induced relapses, the statistical analysis did not confirm 
this observation.
Colonising microbes inhabiting the intestinal mucosa are 
important for normal intestinal function and homeostasis. 
Dysbiosis develops when the composition of intestinal 
microbiome is unfavourable, and this condition may lead 
to various diseases. Altered microbiome may be a cause 
or consequence of a disease, but it may develop parallel 
with an abnormal condition (29). The balance of intestinal 
homeostasis is a sensitive system of intestinal microbiota, 
epithelium and immune cells (30). An alteration of colo-
nic microbiota has been suggested in IBD (31), given that 
intestinal flora is altered in patients who relapse, which in 
turn allows the unopposed proliferation of C. difficile and 
Candida. The frequency of the community-acquired C. 
difficile infection has been increasing worldwide with inci-
dence rates of 3 to 40% (10–12). Candida was presented in 
9.9% among the enrolled subjects. Presence of Candida in 
gastrointestinal tract is commonly benign, but in suscep-
tible individuals with low level of inflammation (eg. IBD) 
may promote colonisation that promotes further inflam-
mation, thus may become a trigger factor (32). The role of 
C. difficile may be the similar. Our data showed 42.2% of 
occurrences of C. difficile positivity in IBD outpatients, and 
53.8% of the patients in the relapse cohort were C. difficile 
toxin positive. We revealed a significant difference regar-
ding C. difficile positivity between IBD patients in relapse 
and those in remission. The occurrences of toxigenic C. dif-
ficile and Candida positivity were excessively high in our 
patients in an acute relapse, which suggests the importan-
ce of intestinal microbiota in IBD; therefore, in conclusion 
we recommend a faecal microbiological examination in 
every relapse to optimise therapy.
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